Table 4 Comparison of MRD evaluation in the BM and PB

CMMC

n = 122

MRD in BM: 5-color MFC

MRD in PB: MACS (CD138) combined with 5-color MFC

1. MRD-positive BM samples were accompanied by PB-MRD-positive results in 88% of corresponding PB samples

2. 100% of MRD-negative BM samples were accompanied by MRD-negative PB samples in NDMM, RRMM and MM achieved PR

[23]

CMMC

n = 45

MRD in BM and PB: 8-color MFC

1. 100% of PB-MRD-positive patients were BM-MRD-positive

2. 56% of PB-MRD-negative patients were BM-MRD-negative

[72]

CMMC

n = 137

MRD in BM and PB: NGF

1. 100% of PB-MRD-positive patients were BM-MRD-positive

2. 46/101 of PB-MRD-negative patients were BM-MRD-negative

[38]

CMMC

n = 42

MRD in BM and PB: RT-qPCR of IGH rearrangements

1. 100% of BM-MRD-negative patients were PB-MRD-negative before/after transplantation

2. 47% of BM-MRD-positive patients were PB-MRD-positive before transplantation

3. 33% of BM-MRD-positive patients were PB-MRD-positive after transplantation

[5]

cfDNA

n = 42

MRD in BM and PB:

NGS of clonal Ig gene rearrangements

1. 89% of PB-MRD-positive patients were BM-MRD-positive

2. 36% of PB-MRD-negative patients were BM-MRD-negative

[55]

cfDNA

n = 22

MRD in BM: MACS (CD138) combined with 8-color MFC

MRD in PB: NGS of IGH rearrangements

The BM-MRD status evaluated by MFC was highly correlated with the PB-MRD evaluated by ctDNA analysis

[12]

cfDNA

n = 45

MRD in BM: 8-color MFC

MRD in PB: ASO-qPCR of IGH rearrangements

1. 5/6 of BM-MRD-negative patients were PB-MRD-negative

2. 2/6 of BM-MRD-positive patients were PB-MRD-negative

[8]